Figure 1
Total number of patients admitted to NPCC in 2017/18
Figure 2
Olanzapine serum concentrations in patient 2 over four days of hospitalisation after the second admission for overdosing three months apart
Table 1
Patients with serum olanzapine concentrations above the lethal threshold of 1 mg/L
| Patient | Sex | Age | Ingested dose | Time from ingestion to blood collection | Concentration (mg/L) | PSS |
|---|---|---|---|---|---|---|
| 1 | male | 26 | about 150 mg | 6 h | 3.40 | 2 |
| 2 | female | 26 | 1680 mg | 5 h | 2.44 | 3 |
| unknown | >12 h | 1.75 | 3 | |||
| 3 | female | 59 | 560 mg | 3 h | 1.53* | 4 |
| 4 | male | 43 | unknown | >24 h | 1.18 | 3 |
Figure 3
Olanzapine serum concentrations in overdosed patient 4 over six days with fatal outcome
Table 2
Serum concentrations of co-ingested drugs (mg/L) during the hospitalisation
| Day | Olanzapine (mg/L) | Clozapine (mg/L) | Norclozapine (mg/L) | Lamotrigine (mg/L) | Midazolam (mg/L) | Zolpidem (mg/L) |
|---|---|---|---|---|---|---|
| 1 | 0.28 | 0.29 | 0.02 | 3.62 | 0.21 | 0.83 |
| 2 | 0.42 | 0.22 | 0.03 | 2.19 | <LOD | 0.19 |
| 3 | 0.59 | 0.49 | <LOD | 2.74 | <LOD | 0.15 |
| 4 | 1.53 | 0.68 | <LOD | 3.5 | <LOD | 0.14 |
| 5 | 0.31 | 0.7 | <LOD | < 1.0 | <LOD | 0.06 |
Figure 4
Olanzapine serum concentrations in a 50-year-old patient who ingested 120 mg of olanzapine
Figure 5
Creatinine kinase levels (IU/L) in hospitalised male (a) and female (b) patients with lines representing threshold values (300 IU/L for men and 200 IU/L for women)